Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites

NCT01065246 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Ascites Due to Epithelial Carcinoma

Interventions

DRUG: catumaxomab

Sponsor

Neovii Biotech